Evidence map›Paper›PMID 35696251›Full record

ArticleThe Journal of pathology2022

Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers.

Bin Liu, Hiroto Katoh, Daisuke Komura, Asami Yamamoto, Mieko Ochi, Takumi Onoyama, Hiroyuki Abe, Tetsuo Ushiku, Yasuyuki Seto, Jian Suo and 1 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Neanderthal adaptive introgression shapedProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Bin LiuDepartment of Gastrocolorectal Surgery, The First Hospital of Jilin University, Changchun, PR China.
Hiroto KatohDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9440-728X
Daisuke KomuraDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0038-728X
Asami YamamotoDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mieko OchiDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takumi OnoyamaDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki AbeDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jian SuoDepartment of Gastrocolorectal Surgery, The First Hospital of Jilin University, Changchun, PR China.
Shumpei IshikawaDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4392-090X
The University of Tokyo · JPJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficient molecular targeting therapies for most gastric cancers (GCs) are currently lacking, despite GC being one of the most frequent and often devastating malignancies worldwide. Thus, identification of novel therapeutic targets for GC is in high demand. Recent advancements of high-throughput nucleic acid synthesis methods combined with next-generation sequencing (NGS) platforms have made it feasible to conduct functional genomics screening using large-scale pooled lentiviral libraries aimed at discovering novel cancer therapeutic targets. In this study, we performed NGS-based functional genomics screening for human GC cell lines using an originally constructed 6,399 shRNA library targeting all 2,096 human metabolism genes. Our screening identified aspartyl-tRNA synthetase (DARS) as a possible candidate for a therapeutic target for GC. In-house tissue microarrays containing 346 cases of GC combined with public datasets showed that patients with high expression levels of DARS protein exhibited more advanced clinicopathologic parameters and a worse prognosis, specifically among diffuse-type GC patients. Both in vitro and in vivo experiments concretely evidenced that DARS inhibition achieved robust growth suppression of GC cells. Moreover, RNA sequencing of GC cell lines under shRNA-mediated DARS knockdown suggested that DARS inhibition exerts its effect through the inactivation of multiple p-ERK pathways. This MAPK-related growth suppression by DARS inhibition would also be applicable to other cancers; thus, it is warranted to investigate the expression and clinical significance of DARS in a wide spectrum of malignancies. Taken together, NGS-based high-throughput pooled lentiviral screening showed DARS as a novel prognostic marker and a promising therapeutic target for GC. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Aspartate-tRNA LigaseStomach NeoplasmsCell Line, TumorEarly Detection of CancerGene Knockdown TechniquesGenomicsHumansPrognosisRNA, Small InterferingAspartate-tRNA LigaseRNA, Small InterferingDARSfunctional genomics screeninggastric cancerprognostic markertherapeutic target

Identifiers

PMID35696251
OpenAlexW4282581017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.